Updates in the Management of Agitation Associated with Dementia Due to Alzheimer\'s Disease
Tuesday, March 26, 2024
6:30 PM – 8:00 PM ET simulcast
5:30 PM – 7:00 PM CT
4:30 PM – 6:00 PM MT
3:30 PM – 5:00 PM PT
1.5 CME/CNE Credit
Features:
- Online personalized quality-improvement poster-generation portal
- Downloadable whiteboard animations and case study video
- Agitation in Alzheimer’s Disease educational web resource
Learning Objectives
- Describe the pathophysiology of agitation in Alzheimer’s disease (AD), including changes in neurotransmitter levels, eg, norepinephrine, serotonin, and dopamine
- Evaluate screening best practices to identify AD-related agitation
- Describe the pharmacologic profile and clinical data of current and emerging agents for the management of AD-related agitation
- Recognize the impact agitation has on patient/caregiver quality of life
- Identify opportunities for caregivers to manage agitation in patients with AD-associated agitation
Target Audience
This initiative is designed to meet the educational needs of primary care clinicians, geriatricians, psychiatrists, and neurologists as well as patients and caregivers concerning the identification of agitation associated with Alzheimer’s disease and appropriate management strategies.
Physician Credit Designation Statement
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
Joint Accreditation Statement
Nurses (ANCC) Credit Designation
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure Of Unlabeled Use
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
This activity is provided by Med Learning Group
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Release date: March 26, 2024
Expiration date: March 26, 2024
Estimated time to completion: 1.5 hours
